Judge Blocks Rival Botox Drug In Trade Secrets Trial

Law360, Los Angeles (March 7, 2012, 9:18 PM EST) -- A California federal judge on Tuesday barred Merz Pharmaceuticals LLC from selling wrinkle-reducing drug Xeomin, just days before the Botox competitor’s nationwide launch, in a bench trial over allegations the company's employees stole trade secrets from Botox maker and rival Allergan Inc.

U.S. District Judge Andrew J. Guilford issued the order after closing arguments in the 11-day bench trial Tuesday, according to a court official, saying he will issue a written order setting out the full terms and duration of the injunction Friday.

Tuesday’s ruling marked...
To view the full article, register now.



Case Information

Case Title

Allergan Inc v. Merz Pharmaceuticals LLC et al

Case Number



California Central

Nature of Suit

Labor: Other


Andrew J. Guilford

Date Filed

March 18, 2011

Law Firms


Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.